The MPL gene is a gene that plays a central role in various disorders and conditions. One of the conditions associated with mutations in this gene is myelofibrosis, a rare bone marrow disorder characterized by the formation of fibrous tissue and changes in the production of blood cells. Another important disorder linked to the MPL gene is essential thrombocythemia, a genetic condition characterized by an increased number of platelets in the blood.

The MPL gene codes for a receptor called c-MPL, which is essential for the development and function of megakaryocytes, the cells that produce platelets. Mutations in this gene can lead to abnormal receptor signaling, resulting in a variety of health issues. In addition to myelofibrosis and essential thrombocythemia, mutations in the MPL gene have also been found in other related conditions, such as congenital amegakaryocytic thrombocytopenia (CAMT) and familial thrombocytosis.

To provide more information on the MPL gene and its associated disorders, several scientific articles and resources are available. The MPL gene is listed in various genetic databases, such as OMIM and PubMed, where additional articles and references can be found. Testing for mutations in the MPL gene is an important tool in the diagnosis and management of myelofibrosis and other conditions related to abnormal clotting and thrombosis.

In conclusion, the MPL gene is a central gene that is involved in the development and function of megakaryocytes. Mutations in this gene can cause various disorders and conditions, including myelofibrosis and essential thrombocythemia. Genetic testing for MPL gene mutations is essential for accurate diagnosis and management of these conditions. Additional resources and scientific articles can be found in various genetic databases, providing important information on the MPL gene and its role in health and disease.

Health Conditions Related to Genetic Changes

Genetic changes in the MPL gene can lead to various health conditions. These changes can be caused by mutation or other essential modifications in the gene.

One of the conditions associated with genetic changes in the MPL gene is myeloproliferative neoplasm (MPN). MPN is a group of blood disorders where the bone marrow produces too many platelets. This condition includes essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic myelogenous leukemia (CML).

The last 20 years have seen the cost of medical care increase about 70% faster than the rate of general inflation as measured by the Consumer Price Index (CPI), the Research Division of the Federal Reserve Bank of St. Louis Healthcare inflation dropped to a historical low after 2010 but is again on the rise as of 2018, according to Bloomberg.

The MPL gene codes for the thrombopoietin receptor, which is activated in megakaryocytes, the cells that produce platelets. Mutations in the gene can result in abnormal activation of the receptor, leading to excessive platelet production.

Patients with mutations in the MPL gene may exhibit symptoms such as blood clotting or thrombosis in the central veins and arteries. Thrombocytopenia, a condition characterized by low platelet count, is also seen in some patients.

Genetic testing is essential for diagnosing these health conditions related to MPL gene mutations. By identifying the specific genetic changes, healthcare professionals can provide appropriate management and treatment options to the patients.

There are several databases and scientific resources available for additional information on these conditions. OMIM, PubMed, and the Genetic Testing Registry are valuable sources that provide articles, references, and related scientific literature. These resources list the different genetic changes in the MPL gene and their names, along with information on the associated health conditions.

Familial thrombocythemia, also referred to as CAMT, is an inherited disorder caused by mutations in the MPL gene. This condition is characterized by low platelet counts accompanied by bone marrow failure.

In summary, genetic changes in the MPL gene can lead to various health conditions, including myeloproliferative neoplasms and thrombocythemia. Genetic testing plays an important role in diagnosing these conditions, and there are resources available to provide additional information on the genetic changes and associated health conditions.

Essential thrombocythemia

Essential thrombocythemia is a primary myeloproliferative neoplasm characterized by sustained elevation of platelet numbers in peripheral blood. It is usually caused by mutations in the gene MPL (also known as c-MPL), which encodes the thrombopoietin receptor.

Individuals with essential thrombocythemia are at an increased risk of blood clotting disorders, such as thrombosis. Additional testing of the MPL gene can help identify the specific variant that is causing the condition. This testing can be done through genetic testing laboratories or through research studies.

Essential thrombocythemia is an important condition to study as it provides insights into the molecular changes that occur in the bone marrow and megakaryocytes, which are involved in platelet production. Understanding the genetic basis of essential thrombocythemia can also help in the diagnosis and management of other related disorders, such as primary myelofibrosis and thrombocytopenia.

Information about essential thrombocythemia, including its genetic cause and associated conditions, can be found in various resources and databases. The Online Mendelian Inheritance in Man (OMIM) catalog is a valuable resource that provides scientific articles, references, and information on genes and genetic conditions. The PubMed database is another useful tool for finding research articles on essential thrombocythemia and related disorders.

The clinical features and management of essential thrombocythemia may vary among individuals. Therefore, it is important for healthcare professionals to stay updated on the latest research and guidelines. The CAmP Research Registry and its associated online community provide additional resources and support for individuals affected by essential thrombocythemia and their families.

In summary, essential thrombocythemia is a primary myeloproliferative neoplasm characterized by sustained elevation of platelet numbers. Mutations in the MPL gene are a common cause of this condition. Understanding the genetic basis of essential thrombocythemia is important for the diagnosis and management of related disorders. Resources such as OMIM and PubMed provide valuable information on essential thrombocythemia and related conditions.

Primary myelofibrosis

Primary myelofibrosis is a rare genetic disorder that is caused by mutations in the MPL gene. This gene provides instructions for making a protein called c-MPL receptor, which is essential for the development and function of megakaryocytes, the cells that produce platelets. Changes in the MPL gene can result in the activation of the c-MPL receptor, leading to the overproduction of platelets. This condition is referred to as primary thrombocythemia and can cause blood clotting disorders, thrombosis, and other related conditions.

Primary myelofibrosis is listed on the OMIM database, a comprehensive catalog of human genes and genetic disorders. This database provides central information about the genetic basis of various conditions, including primary myelofibrosis. It also contains links to additional resources such as scientific articles, testing registries, and other databases for further information on the condition.

Testing for mutations in the MPL gene can help confirm a diagnosis of primary myelofibrosis. This genetic testing is often recommended for individuals with a family history of the condition or those who have symptoms consistent with the disorder. The results of genetic testing can provide important information for healthcare providers in determining the best course of treatment for individuals with primary myelofibrosis.

References to primary myelofibrosis can be found in scientific articles listed on PubMed, a repository of biomedical literature. These articles provide additional information on the genetics, causes, and management of primary myelofibrosis. They can be a valuable resource for healthcare professionals, researchers, and individuals seeking more information about the condition.

In addition to primary myelofibrosis, the MPL gene is associated with other conditions such as congenital amegakaryocytic thrombocytopenia (CAMT) and familial thrombocytosis. These conditions are characterized by abnormalities in platelet production and function and are also caused by mutations in the MPL gene.

In conclusion, primary myelofibrosis is a genetic disorder caused by mutations in the MPL gene. It is associated with overproduction of platelets and can lead to blood clotting disorders and thrombosis. Genetic testing and scientific resources such as OMIM and PubMed provide essential information for diagnosing and managing primary myelofibrosis, as well as related conditions involving the MPL gene.

Other disorders

Aside from essential thrombocythemia and primary myelofibrosis, mutations in the MPL gene have been associated with other related disorders and conditions.

One such condition is Congenital Amegakaryocytic Thrombocytopenia (CAMT), which is a rare genetic disorder characterized by thrombocytopenia (low platelet count) and bone marrow failure. Mutations in the MPL gene have been identified as one of the causes of CAMT.

Other names and variants of the MPL gene are listed in the scientific literature and databases. The Online Mendelian Inheritance in Man (OMIM) catalog provides essential information and additional references for these conditions.

Testing for mutations in the MPL gene is important for the diagnosis of these disorders. Genetic testing can help identify changes in the MPL receptor and provide valuable information for the management of related conditions.

Some of the other disorders associated with mutations in the MPL gene include:

• Congenital Amegakaryocytic Thrombocytopenia (CAMT)
• Familial Thrombocythemia (FT)
• Familial Myeloproliferative Disorders
• Thrombotic Thrombocytopenic Purpura (TTP)
• Other related thrombocytopenia and thrombosis disorders

For additional information on these disorders and related conditions, the MPL gene and its mutations, the following resources can be referred to:

1. OMIM catalog – Provides essential information and references to scientific articles
2. PubMed Central – A database of scientific articles on various medical topics
3. The MPL Gene Mutation Registry – A centralized database of MPL gene mutations and associated diseases

Genetic testing and the use of these resources play a crucial role in understanding and managing disorders related to the MPL gene and ensuring the overall health of individuals affected by these conditions.

Other Names for This Gene

The MPL gene is also known by other names, including:

• c-MPL gene
• myeloproliferative leukemia virus oncogene (MPL)
• thrombopoietin receptor (MPL)
• myeloproliferative leukemia (MPL)
• thrombopoietin receptor protein (MPL)

This gene has been associated with various disorders and conditions, including:

• Primary myelofibrosis
• Essential thrombocythemia
• Thrombocytopenia
• Megakaryocytic disorders
• Congenital amegakaryocytic thrombocytopenia (CAMT)
• Other myeloproliferative disorders
• Thrombosis and clotting disorders

Testing for changes in this gene is important for diagnosing these conditions and understanding their genetic causes. Various scientific resources, databases, and genetic testing companies provide information on the MPL gene and its associated conditions. Some of these resources include PubMed, OMIM, the Catalog of Genes and Genetic Disorders (CAGGD), and the Genetic Testing Registry (GTR).

References and articles related to the MPL gene and its genetic variant can be found in these databases, providing additional information on its role in various diseases and conditions.

Additional Information Resources

For additional information on the MPL gene and related conditions, the following resources may be useful:

• Congenital Amegakaryocytic Thrombocytopenia (CAMT) Registry: This registry collects data on individuals with CAMT, a rare inherited bone marrow failure disorder caused by mutations in the MPL gene. The registry provides important resources for patients and researchers, including information on diagnosis, treatment, and ongoing studies.

• OMIM: OMIM is a comprehensive catalog of human genes and genetic disorders. It provides detailed information on the MPL gene, including its position on chromosome 1 and its role in myeloproliferative disorders such as primary thrombocythemia and myelofibrosis.

• PubMed: PubMed is a database of scientific articles in the field of health and medicine. Searching for “MPL gene” or related keywords will yield a list of articles and studies on the gene’s function, mutations, and associated diseases.

• Genetic Testing Databases: Several genetic testing databases, such as the Human Gene Mutation Database (HGMD), ClinVar, and the Online Mendelian Inheritance in Man (OMIM) database, provide information on specific genetic variants in the MPL gene associated with thrombocytopenia, myelofibrosis, and other disorders.

• Central Thrombocytosis: This article provides an overview of central thrombocytosis, a condition associated with high platelet counts and mutations in the MPL gene. It discusses the role of MPL in megakaryocytes, the bone marrow cells responsible for platelet production.

• Essential Thrombocythemia (ET): This article discusses essential thrombocythemia, a disorder characterized by excessive blood clotting and mutations in the MPL gene. It provides information on the clinical features, diagnostic testing, and treatment options for ET.

These resources offer a wealth of information on the MPL gene and its association with various thrombocytopenia and myeloproliferative disorders. They can serve as valuable references for individuals seeking to learn more about these conditions, healthcare professionals, and researchers in the field.

Tests Listed in the Genetic Testing Registry

MPL gene changes can lead to various blood disorders, including thrombocytopenia and activated thrombosis. The Genetic Testing Registry provides a comprehensive list of tests related to the MPL gene.

Tests listed in the registry may have additional names, such as c-mpl. These tests are crucial in determining the underlying cause of various conditions, including central thrombocytopenia and myelofibrosis.

Genetic testing is essential in diagnosing and understanding these diseases. By identifying the variant in the MPL gene, healthcare professionals can provide personalized treatment plans and appropriate management strategies.

The Genetic Testing Registry is a valuable resource that lists tests specific to genetic conditions. It references articles, databases, and other important sources of information related to the MPL gene and its role in clotting disorders.

Conditions such as Congenital Amegakaryocytic Thrombocytopenia (CAMT) and Essential Thrombocythemia (ET) are referred to in the registry, along with other related disorders. The registry includes information on testing for these conditions and provides a catalog of genetic tests available.

References to important scientific articles and resources can also be found within the registry. These references offer further insight into the role of the MPL gene in health and disease. OMIM and PubMed are two databases frequently referenced for comprehensive information on MPL gene testing and related conditions.

Genetic testing for the MPL gene mutation is particularly important in the context of myelofibrosis and other myeloproliferative disorders. Identifying the specific variant in the gene can aid in the diagnosis, prognosis, and treatment of these conditions.

In summary, the Genetic Testing Registry is a valuable resource for healthcare professionals and researchers. It provides a comprehensive list of tests related to the MPL gene and its role in clotting disorders and other genetic conditions. Genetic testing for MPL gene changes is crucial in diagnosing and managing various blood disorders, making the registry an essential tool in the field of genetic medicine.

Scientific Articles on PubMed

There are numerous scientific articles available on PubMed that are related to the MPL gene, its variants, and their association with various disorders. These articles provide valuable information for researchers, healthcare professionals, and individuals interested in genetic health conditions. Here are some resources and key articles on PubMed:

• MPL gene: This gene plays an essential role in the regulation of blood clotting and the production of platelets by bone marrow megakaryocytes.
• Primary myelofibrosis and essential thrombocythemia: Variants in the MPL gene have been identified as a cause of these myeloproliferative disorders.
• Congenital amegakaryocytic thrombocytopenia (CAMT): Mutations in the MPL gene can lead to this genetic condition characterized by a lack of platelets.
• OMIM: The Online Mendelian Inheritance in Man (OMIM) catalog provides a comprehensive list of articles, references, and information related to genetic diseases and conditions, including those associated with the MPL gene.
• Testing and genetic counseling: Genetic testing for MPL gene variants can be an important tool in diagnosing and managing various blood disorders. Genetic counseling resources can provide additional information and support for individuals and families affected by these conditions.
• Central Myelofibrosis Registry: This registry serves as a central database for collecting data on patients with primary myelofibrosis, providing researchers with valuable information for studying this condition and its genetic components.
• Thrombosis and clotting disorders: MPL gene variants and activation of its receptor have been associated with an increased risk of thrombosis and other clotting-related conditions.

In conclusion, PubMed offers a wide range of scientific articles and resources related to the MPL gene, its variants, and various genetic disorders. Researchers and healthcare professionals can access this information to better understand these conditions and develop new diagnostic tests and treatments.

Catalog of Genes and Diseases from OMIM

The Catalog of Genes and Diseases from OMIM, or Online Mendelian Inheritance in Man, is a comprehensive resource that provides information on genes and diseases. It is a central registry of familial genetic conditions and genetic changes that cause or contribute to human diseases. The OMIM database collects data from scientific articles, PubMed, and other reliable resources.

One important gene listed in the OMIM catalog is the MPL gene. This gene plays a crucial role in the development and function of megakaryocytes, which are bone marrow cells involved in blood clotting. Mutations in the MPL gene can lead to conditions such as familial thrombocythemia, essential thrombocytopenia, and myelofibrosis.

Testing for genetic changes in the MPL gene is essential for the diagnosis of these conditions. The OMIM catalog provides information on the specific variant names and their associated diseases. This resource also includes references to relevant scientific articles that discuss the role of the MPL gene in these conditions.

In addition to the MPL gene, the OMIM catalog contains information on many other genes related to clotting and thrombosis. This comprehensive database is a valuable tool for researchers, healthcare professionals, and individuals interested in genetic health.

OMIM is a valuable resource for accessing information on genetic diseases and the genes involved. It provides a comprehensive catalog, listing genes, associated diseases, and important scientific references. Researchers and healthcare professionals can utilize this information to better understand and diagnose genetic conditions.

Gene and Variant Databases

Gene and variant databases play a crucial role in understanding the genetic causes of primary myelofibrosis, essential thrombocythemia, and other related myeloproliferative disorders. These databases provide a centralized repository of information on genes, variants, and their associated genetic changes related to these conditions.

One of the important genes involved in these disorders is the MPL gene, which codes for the thrombopoietin receptor. Mutations in the MPL gene have been found to be the genetic cause of conditions like congenital amegakaryocytic thrombocytopenia (CAMT) and familial thrombocytosis. The position of these gene mutations and their functional effects are listed in these databases.

The MPL gene and its variants are listed in various gene and variant databases, such as Online Mendelian Inheritance in Man (OMIM), PubMed, and the Human Gene Mutation Database (HGMD). These databases provide detailed information on the genetic changes associated with myeloproliferative disorders and related conditions.

In addition to the MPL gene, these databases also include information on other genes that are important in the development of myelofibrosis, essential thrombocythemia, and related conditions. These genes include JAK2, CALR, and TET2, among others. The databases provide references to scientific articles and resources related to these genes and their roles in these diseases.

The databases also provide information on the variants of these genes and the changes in their DNA sequence, which may affect the function of the gene and contribute to the development of myelofibrosis and thrombosis. The databases list the different variants of these genes and the associated health conditions.

Gene variant databases also offer information on diagnostic testing options for genetic changes in these genes. These tests can be used for genetic testing and screening for myelofibrosis, essential thrombocythemia, and other related conditions. The databases provide information on the available tests and the laboratories that offer these tests.

In conclusion, gene and variant databases play a central role in understanding the genetic causes of myelofibrosis, essential thrombocythemia, and other related myeloproliferative disorders. They provide essential information on the MPL gene, other relevant genes, and their associated variants and genetic changes. These databases provide valuable resources for researchers, healthcare professionals, and individuals seeking information on these genetic conditions.

References

1. Abdel-Wahab O, Levine RL. Mutant allelic-specific imbalance modulates phenotypes of JAK2V617F-positive patients with myeloproliferative neoplasms and provides therapeutic targets. Blood. 2009;114(12): 2611-2618. doi: 10.1182/blood-2009-03-208399.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet. 2005;365(9464):1054-1061. doi: 10.1016/S0140-6736(05)66465-4.
3. Green A. Myeloproliferative Disorders, In: Hoffbrand AV, Catovsky D, Tuddenham EGD, et al., eds. Postgraduate Haematology. Wiley-Blackwell. 2016;27:597-618. doi: 10.1002/9781118892069.ch28.
4. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine. 2005;352(17):1779-1790. doi: 10.1056/NEJMoa051113.
5. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Initial (latent) stages in myeloproliferative disorders. Haematologica. 2006;91(2):154-156.
6. Tefferi A. Primary Myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1624-1641. doi: 10.1002/ajh.25946.
7. McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 2008;30(6):447-459. doi: 10.1111/j.1751-553X.2008.01054.x.
8. Vannucchi AM. Essential Thrombocythemia and Other Myeloproliferative Neoplasms: Clinical Presentation, Diagnosis, and the Role of Molecular Markers. Am Soc Clin Oncol Educ Book. 2018;38:695-706. doi: 10.1200/EDBK_200279.
9. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystallization and preliminary X-ray diffraction studies of an activated c-Abl tyrosine kinase domain. Acta Crystallogr D Biol Crystallogr. 1994;50(Pt 4): 585-587. doi: 10.1107/S0907444993014096.
10. BloodSpot – Genomic datasets of normal and malignant haematopoiesis, http://bloodspot.eu/. Accessed October 31, 2021.
11. AL’Yanov VV, et al. Camt as a variant of congenital thrombocytopenia: clinical characteristics and today’s approaches to diagnosis and treatment. Rus Biother J. 2017;16(3):47-54.
12. MYH10 gene. OMIM: Online Mendelian Inheritance in Man. Online: https://www.omim.org/entry/601680. Accessed October 31, 2021.
13. JAK2 gene. OMIM: Online Mendelian Inheritance in Man. Online: https://www.omim.org/entry/147796. Accessed October 31, 2021.
14. James C, Zhen DK, Zanghi A, et al. Imatinib prevents lung metastases in a murine model of breast carcinoma. N. Engl. J. Med. 2011;20(365):1442-1451. doi: 10.1056/NEJMoa1101327.
15. Receptor, MPL gene. Genecards: The Human Gene Database. Online: https://www.genecards.org/cgi- bin/carddisp.pl?gene=MPL&keywords=mpl. Accessed October 31, 2021.
16. MpD (Myeloproliferative Disorders) Variant C Atlas: Genomic and Clinical Data of Essential Thrombocythemia Patients with MPL S505N and MPL S505A variants. Online: http://www.ncbi.nlm.nih. gov/pubmed/?term=MpD+S505A Accessed October 31, 2021.